Benign prostatic hyperplasia (BPH) is a medical term that is used to describe enlargement of the prostate gland. It is not a cancer and is usually not a serious threat to health if well-treated. Most males aged 50 years and above develop BPH. As the prostate gets bigger, it can place pressure on the bladder and it may squeeze or partly block the tube that carries urine from the bladder out of the body. This often causes problems with passing urine and may also cause other complications such as recurrent urinary tract infections, blockage of the bladder outlet, and kidney failure.
Fexapotide Triflutate is a drug that is under development for the treatment of BPH. It is delivered through an injection directly into the prostate. It acts by shrinking the enlarged prostate tissue without damaging neighbouring tissue and nerves. With only one injection, it leads to a natural cell death within the enlarged prostate, which is believed to reduce the prostatic volume and therefore eliminate symptoms. Fexapotide Triflutate is also thought to have reduced sexual side effects and treatment of frequent night time urination when compared to existing therapies. If licensed, Fexapotide Triflutate will offer an additional treatment option for patients with BPH.